カテゴリー： 世界, 医療/バイオ, LP Information

世界の経口投与ワクチン市場予測 2023年-2029年

【英語タイトル】Global Orally Administered Vaccine Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC01366）・商品コード：LP23DC01366
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：117
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の経口投与ワクチン市場」は、過去の販売実績から2022年の世界の経口投与ワクチンの総販売量を検討し、2023年から2029年の予測される経口投与ワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の経口投与ワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の経口投与ワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の経口投与ワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の経口投与ワクチン市場における各社の独自のポジションをより深く理解するために、経口投与ワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の経口投与ワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。経口投与ワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。経口投与ワクチンの中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。経口投与ワクチンのヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

経口投与ワクチンの世界主要メーカーとしては、Merck、 GSK、 Sanofi、 Lanzhou Institute、 Serum Institute、 Valneva、 Shanghai United Cell、 Bibcol、 PaxVax、 Vabiotech、 Tiantan Biological、 EuBiologics、 Panacea Biotec Ltd、 Bio-Med、 Halfkin Bio-Pharmaceuticalsなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の経口投与ワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では経口投与ワクチン市場をセグメンテーションし、種類別 (ロタウイルスワクチン、コレラワクチン、経口ポリオワクチン、その他)、用途別 (公的関与、民間)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：ロタウイルスワクチン、コレラワクチン、経口ポリオワクチン、その他

・用途別区分：公的関与、民間

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の経口投与ワクチン市場の10年間の市場状況・展望は？
・世界および地域別に見た経口投与ワクチン市場成長の要因は何か？
・経口投与ワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか？
・経口投与ワクチンのタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：経口投与ワクチンの年間販売量2018-2029、地域別現状・将来分析
・経口投与ワクチンの種類別セグメント：ロタウイルスワクチン、コレラワクチン、経口ポリオワクチン、その他
・経口投与ワクチンの種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・経口投与ワクチンの用途別セグメント：公的関与、民間
・経口投与ワクチンの用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の経口投与ワクチン市場
・企業別のグローバル経口投与ワクチン市場データ：2018-2023年の年間販売量、市場シェア
・企業別の経口投与ワクチンの年間売上：2018-2023年の売上、市場シェア
・企業別の経口投与ワクチン販売価格
・主要企業の経口投与ワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

経口投与ワクチンの地域別レビュー
・地域別の経口投与ワクチン市場規模2018-2023：年間販売量、売上
・主要国別の経口投与ワクチン市場規模2018-2023：年間販売量、売上
・南北アメリカの経口投与ワクチン販売の成長
・アジア太平洋の経口投与ワクチン販売の成長
・ヨーロッパの経口投与ワクチン販売の成長
・中東・アフリカの経口投与ワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の経口投与ワクチン販売量、売上（2018-2023）
・南北アメリカの経口投与ワクチンの種類別販売量
・南北アメリカの経口投与ワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の経口投与ワクチン販売量、売上（2018-2023）
・アジア太平洋の経口投与ワクチンの種類別販売量
・アジア太平洋の経口投与ワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の経口投与ワクチン販売量、売上（2018-2023）
・ヨーロッパの経口投与ワクチンの種類別販売量
・ヨーロッパの経口投与ワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の経口投与ワクチン販売量、売上（2018-2023）
・中東・アフリカの経口投与ワクチンの種類別販売量
・中東・アフリカの経口投与ワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・経口投与ワクチンの製造コスト構造分析
・経口投与ワクチンの製造プロセス分析
・経口投与ワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・経口投与ワクチンの主要なグローバル販売業者
・経口投与ワクチンの主要なグローバル顧客

地域別の経口投与ワクチン市場予測レビュー
・地域別の経口投与ワクチン市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・経口投与ワクチンの種類別市場規模予測
・経口投与ワクチンの用途別市場規模予測

主要企業分析
Merck、 GSK、 Sanofi、 Lanzhou Institute、 Serum Institute、 Valneva、 Shanghai United Cell、 Bibcol、 PaxVax、 Vabiotech、 Tiantan Biological、 EuBiologics、 Panacea Biotec Ltd、 Bio-Med、 Halfkin Bio-Pharmaceuticals
・企業情報
・経口投与ワクチン製品
・経口投与ワクチン販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Orally Administered Vaccine market size is projected to grow from US$ 2484.8 million in 2022 to US$ 3707.1 million in 2029; it is expected to grow at a CAGR of 5.9% from 2023 to 2029.
United States market for Orally Administered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Orally Administered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Orally Administered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Orally Administered Vaccine players cover Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. 
LPI (LP Information)’ newest research report, the “Orally Administered Vaccine Industry Forecast” looks at past sales and reviews total world Orally Administered Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Orally Administered Vaccine sales for 2023 through 2029. With Orally Administered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orally Administered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Orally Administered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orally Administered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Orally Administered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orally Administered Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orally Administered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Orally Administered Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segmentation by application
Public
Private
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Orally Administered Vaccine market?
What factors are driving Orally Administered Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Orally Administered Vaccine market opportunities vary by end market size?
How does Orally Administered Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Orally Administered Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Orally Administered Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Orally Administered Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Orally Administered Vaccine Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.2.4 Other
2.3 Orally Administered Vaccine Sales by Type
2.3.1 Global Orally Administered Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Orally Administered Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Orally Administered Vaccine Sale Price by Type (2018-2023)
2.4 Orally Administered Vaccine Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Orally Administered Vaccine Sales by Application
2.5.1 Global Orally Administered Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Orally Administered Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Orally Administered Vaccine Sale Price by Application (2018-2023)
3 Global Orally Administered Vaccine by Company
3.1 Global Orally Administered Vaccine Breakdown Data by Company
3.1.1 Global Orally Administered Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Orally Administered Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Orally Administered Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Orally Administered Vaccine Revenue by Company (2018-2023)
3.2.2 Global Orally Administered Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Orally Administered Vaccine Sale Price by Company
3.4 Key Manufacturers Orally Administered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Orally Administered Vaccine Product Location Distribution
3.4.2 Players Orally Administered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Orally Administered Vaccine by Geographic Region
4.1 World Historic Orally Administered Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Orally Administered Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Orally Administered Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Orally Administered Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Orally Administered Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Orally Administered Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Orally Administered Vaccine Sales Growth
4.4 APAC Orally Administered Vaccine Sales Growth
4.5 Europe Orally Administered Vaccine Sales Growth
4.6 Middle East & Africa Orally Administered Vaccine Sales Growth
5 Americas
5.1 Americas Orally Administered Vaccine Sales by Country
5.1.1 Americas Orally Administered Vaccine Sales by Country (2018-2023)
5.1.2 Americas Orally Administered Vaccine Revenue by Country (2018-2023)
5.2 Americas Orally Administered Vaccine Sales by Type
5.3 Americas Orally Administered Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orally Administered Vaccine Sales by Region
6.1.1 APAC Orally Administered Vaccine Sales by Region (2018-2023)
6.1.2 APAC Orally Administered Vaccine Revenue by Region (2018-2023)
6.2 APAC Orally Administered Vaccine Sales by Type
6.3 APAC Orally Administered Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Orally Administered Vaccine by Country
7.1.1 Europe Orally Administered Vaccine Sales by Country (2018-2023)
7.1.2 Europe Orally Administered Vaccine Revenue by Country (2018-2023)
7.2 Europe Orally Administered Vaccine Sales by Type
7.3 Europe Orally Administered Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Orally Administered Vaccine by Country
8.1.1 Middle East & Africa Orally Administered Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Orally Administered Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Orally Administered Vaccine Sales by Type
8.3 Middle East & Africa Orally Administered Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Orally Administered Vaccine
10.3 Manufacturing Process Analysis of Orally Administered Vaccine
10.4 Industry Chain Structure of Orally Administered Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Orally Administered Vaccine Distributors
11.3 Orally Administered Vaccine Customer
12 World Forecast Review for Orally Administered Vaccine by Geographic Region
12.1 Global Orally Administered Vaccine Market Size Forecast by Region
12.1.1 Global Orally Administered Vaccine Forecast by Region (2024-2029)
12.1.2 Global Orally Administered Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Orally Administered Vaccine Forecast by Type
12.7 Global Orally Administered Vaccine Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Orally Administered Vaccine Product Portfolios and Specifications
13.1.3 Merck Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Orally Administered Vaccine Product Portfolios and Specifications
13.2.3 GSK Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Orally Administered Vaccine Product Portfolios and Specifications
13.3.3 Sanofi Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications
13.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Orally Administered Vaccine Product Portfolios and Specifications
13.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Orally Administered Vaccine Product Portfolios and Specifications
13.6.3 Valneva Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications
13.7.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Orally Administered Vaccine Product Portfolios and Specifications
13.8.3 Bibcol Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Orally Administered Vaccine Product Portfolios and Specifications
13.9.3 PaxVax Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Orally Administered Vaccine Product Portfolios and Specifications
13.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications
13.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Orally Administered Vaccine Product Portfolios and Specifications
13.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Orally Administered Vaccine Product Portfolios and Specifications
13.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Orally Administered Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Orally Administered Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Major Players of Other
Table 7. Global Orally Administered Vaccine Sales by Type (2018-2023) & (K Units)
Table 8. Global Orally Administered Vaccine Sales Market Share by Type (2018-2023)
Table 9. Global Orally Administered Vaccine Revenue by Type (2018-2023) & ($ million)
Table 10. Global Orally Administered Vaccine Revenue Market Share by Type (2018-2023)
Table 11. Global Orally Administered Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Orally Administered Vaccine Sales by Application (2018-2023) & (K Units)
Table 13. Global Orally Administered Vaccine Sales Market Share by Application (2018-2023)
Table 14. Global Orally Administered Vaccine Revenue by Application (2018-2023)
Table 15. Global Orally Administered Vaccine Revenue Market Share by Application (2018-2023)
Table 16. Global Orally Administered Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Orally Administered Vaccine Sales by Company (2018-2023) & (K Units)
Table 18. Global Orally Administered Vaccine Sales Market Share by Company (2018-2023)
Table 19. Global Orally Administered Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Orally Administered Vaccine Revenue Market Share by Company (2018-2023)
Table 21. Global Orally Administered Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Orally Administered Vaccine Producing Area Distribution and Sales Area
Table 23. Players Orally Administered Vaccine Products Offered
Table 24. Orally Administered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Orally Administered Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Orally Administered Vaccine Sales Market Share Geographic Region (2018-2023)
Table 29. Global Orally Administered Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Orally Administered Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Orally Administered Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Orally Administered Vaccine Sales Market Share by Country/Region (2018-2023)
Table 33. Global Orally Administered Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Orally Administered Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Orally Administered Vaccine Sales by Country (2018-2023) & (K Units)
Table 36. Americas Orally Administered Vaccine Sales Market Share by Country (2018-2023)
Table 37. Americas Orally Administered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Orally Administered Vaccine Revenue Market Share by Country (2018-2023)
Table 39. Americas Orally Administered Vaccine Sales by Type (2018-2023) & (K Units)
Table 40. Americas Orally Administered Vaccine Sales by Application (2018-2023) & (K Units)
Table 41. APAC Orally Administered Vaccine Sales by Region (2018-2023) & (K Units)
Table 42. APAC Orally Administered Vaccine Sales Market Share by Region (2018-2023)
Table 43. APAC Orally Administered Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Orally Administered Vaccine Revenue Market Share by Region (2018-2023)
Table 45. APAC Orally Administered Vaccine Sales by Type (2018-2023) & (K Units)
Table 46. APAC Orally Administered Vaccine Sales by Application (2018-2023) & (K Units)
Table 47. Europe Orally Administered Vaccine Sales by Country (2018-2023) & (K Units)
Table 48. Europe Orally Administered Vaccine Sales Market Share by Country (2018-2023)
Table 49. Europe Orally Administered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Orally Administered Vaccine Revenue Market Share by Country (2018-2023)
Table 51. Europe Orally Administered Vaccine Sales by Type (2018-2023) & (K Units)
Table 52. Europe Orally Administered Vaccine Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Orally Administered Vaccine Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Orally Administered Vaccine Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Orally Administered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Orally Administered Vaccine Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Orally Administered Vaccine Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Orally Administered Vaccine Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Orally Administered Vaccine
Table 60. Key Market Challenges & Risks of Orally Administered Vaccine
Table 61. Key Industry Trends of Orally Administered Vaccine
Table 62. Orally Administered Vaccine Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Orally Administered Vaccine Distributors List
Table 65. Orally Administered Vaccine Customer List
Table 66. Global Orally Administered Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Orally Administered Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Orally Administered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Orally Administered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Orally Administered Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Orally Administered Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Orally Administered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Orally Administered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Orally Administered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Orally Administered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Orally Administered Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Orally Administered Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Orally Administered Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Orally Administered Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Merck Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck Orally Administered Vaccine Product Portfolios and Specifications
Table 82. Merck Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Merck Main Business
Table 84. Merck Latest Developments
Table 85. GSK Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 86. GSK Orally Administered Vaccine Product Portfolios and Specifications
Table 87. GSK Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. GSK Main Business
Table 89. GSK Latest Developments
Table 90. Sanofi Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Orally Administered Vaccine Product Portfolios and Specifications
Table 92. Sanofi Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Lanzhou Institute Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications
Table 97. Lanzhou Institute Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Lanzhou Institute Main Business
Table 99. Lanzhou Institute Latest Developments
Table 100. Serum Institute Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. Serum Institute Orally Administered Vaccine Product Portfolios and Specifications
Table 102. Serum Institute Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Serum Institute Main Business
Table 104. Serum Institute Latest Developments
Table 105. Valneva Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Valneva Orally Administered Vaccine Product Portfolios and Specifications
Table 107. Valneva Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Valneva Main Business
Table 109. Valneva Latest Developments
Table 110. Shanghai United Cell Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications
Table 112. Shanghai United Cell Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Shanghai United Cell Main Business
Table 114. Shanghai United Cell Latest Developments
Table 115. Bibcol Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. Bibcol Orally Administered Vaccine Product Portfolios and Specifications
Table 117. Bibcol Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Bibcol Main Business
Table 119. Bibcol Latest Developments
Table 120. PaxVax Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. PaxVax Orally Administered Vaccine Product Portfolios and Specifications
Table 122. PaxVax Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. PaxVax Main Business
Table 124. PaxVax Latest Developments
Table 125. Vabiotech Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Vabiotech Orally Administered Vaccine Product Portfolios and Specifications
Table 127. Vabiotech Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Vabiotech Main Business
Table 129. Vabiotech Latest Developments
Table 130. Tiantan Biological Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications
Table 132. Tiantan Biological Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Tiantan Biological Main Business
Table 134. Tiantan Biological Latest Developments
Table 135. EuBiologics Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. EuBiologics Orally Administered Vaccine Product Portfolios and Specifications
Table 137. EuBiologics Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. EuBiologics Main Business
Table 139. EuBiologics Latest Developments
Table 140. Panacea Biotec Ltd Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications
Table 142. Panacea Biotec Ltd Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Panacea Biotec Ltd Main Business
Table 144. Panacea Biotec Ltd Latest Developments
Table 145. Bio-Med Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. Bio-Med Orally Administered Vaccine Product Portfolios and Specifications
Table 147. Bio-Med Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Bio-Med Main Business
Table 149. Bio-Med Latest Developments
Table 150. Halfkin Bio-Pharmaceuticals Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications
Table 152. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Halfkin Bio-Pharmaceuticals Main Business
Table 154. Halfkin Bio-Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Orally Administered Vaccine
Figure 2. Orally Administered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Orally Administered Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Orally Administered Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Orally Administered Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rotavirus Vaccine
Figure 10. Product Picture of Cholera Vaccine
Figure 11. Product Picture of Oral Polio Vaccine
Figure 12. Product Picture of Other
Figure 13. Global Orally Administered Vaccine Sales Market Share by Type in 2022
Figure 14. Global Orally Administered Vaccine Revenue Market Share by Type (2018-2023)
Figure 15. Orally Administered Vaccine Consumed in Public
Figure 16. Global Orally Administered Vaccine Market: Public (2018-2023) & (K Units)
Figure 17. Orally Administered Vaccine Consumed in Private
Figure 18. Global Orally Administered Vaccine Market: Private (2018-2023) & (K Units)
Figure 19. Global Orally Administered Vaccine Sales Market Share by Application (2022)
Figure 20. Global Orally Administered Vaccine Revenue Market Share by Application in 2022
Figure 21. Orally Administered Vaccine Sales Market by Company in 2022 (K Units)
Figure 22. Global Orally Administered Vaccine Sales Market Share by Company in 2022
Figure 23. Orally Administered Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Orally Administered Vaccine Revenue Market Share by Company in 2022
Figure 25. Global Orally Administered Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Orally Administered Vaccine Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Orally Administered Vaccine Sales 2018-2023 (K Units)
Figure 28. Americas Orally Administered Vaccine Revenue 2018-2023 ($ Millions)
Figure 29. APAC Orally Administered Vaccine Sales 2018-2023 (K Units)
Figure 30. APAC Orally Administered Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. Europe Orally Administered Vaccine Sales 2018-2023 (K Units)
Figure 32. Europe Orally Administered Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Orally Administered Vaccine Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Orally Administered Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Americas Orally Administered Vaccine Sales Market Share by Country in 2022
Figure 36. Americas Orally Administered Vaccine Revenue Market Share by Country in 2022
Figure 37. Americas Orally Administered Vaccine Sales Market Share by Type (2018-2023)
Figure 38. Americas Orally Administered Vaccine Sales Market Share by Application (2018-2023)
Figure 39. United States Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Orally Administered Vaccine Sales Market Share by Region in 2022
Figure 44. APAC Orally Administered Vaccine Revenue Market Share by Regions in 2022
Figure 45. APAC Orally Administered Vaccine Sales Market Share by Type (2018-2023)
Figure 46. APAC Orally Administered Vaccine Sales Market Share by Application (2018-2023)
Figure 47. China Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Orally Administered Vaccine Sales Market Share by Country in 2022
Figure 55. Europe Orally Administered Vaccine Revenue Market Share by Country in 2022
Figure 56. Europe Orally Administered Vaccine Sales Market Share by Type (2018-2023)
Figure 57. Europe Orally Administered Vaccine Sales Market Share by Application (2018-2023)
Figure 58. Germany Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Orally Administered Vaccine Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Orally Administered Vaccine Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Orally Administered Vaccine Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Orally Administered Vaccine Sales Market Share by Application (2018-2023)
Figure 67. Egypt Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Orally Administered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Orally Administered Vaccine in 2022
Figure 73. Manufacturing Process Analysis of Orally Administered Vaccine
Figure 74. Industry Chain Structure of Orally Administered Vaccine
Figure 75. Channels of Distribution
Figure 76. Global Orally Administered Vaccine Sales Market Forecast by Region (2024-2029)
Figure 77. Global Orally Administered Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Orally Administered Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Orally Administered Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Orally Administered Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Orally Administered Vaccine Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の経口投与ワクチン市場予測 2023年-2029年] (コード：LP23DC01366)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の経口投与ワクチン市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のmRNA新型コロナウイルスワクチン市場予測 2023年-2029年
  • 世界のワクチン製造装置市場予測 2023年-2029年
  • 世界の経口ワクチン投与市場予測 2023年-2029年
  • 世界の吸入用組換え新型コロナウイルスワクチン市場予測 2023年-2029年
  • 世界の経口新型コロナウイルス感染症ワクチン市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆